GGrantIndex
← Leaderboards

Mansun Law

Scripps Research Institute, The

$19,290,800
Attributed
$23,395,663
Total exposure
16
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.2M · FY200825
$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$36,367,869 · 18

By mechanism

R01$14,063,021 · 5
P01$10,236,394 · 5
U19$7,686,267 · 3
R56$1,675,863 · 2
R24$1,651,974 · 1
R21$1,054,350 · 2

Top collaborators

Most similar at Scripps Research Institute, The

Same institution · by research overlap

Others in their field

Top investigators on “Virus

Research focus

VirusHepatitis C VirusAntibodiesVaccinesInfectionNeutralizing AntibodyViralEpitopesAntigensMalignant Neoplasm Of LiverHepatitis C AntibodiesHepatitis CB-LymphocytesHepatitis C VaccineAntibody ResponseReagentGlycoproteinsBaseImmuneProgramsDesignSamplingGenotypeVaccination

Grant awards (61)

Broadly Effective HCV Vaccine$2,111,046
P01 · FY2025 · AI · contact PI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$957,683
R01 · FY2025 · AI
Understanding human antibody responses to chronic viral hepatitis C$618,099
R01 · FY2025 · AI · contact PI
Core 001 - Virology Core$423,271
P01 · FY2025 · AI · contact PI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$160,224
R01 · FY2025 · AI
Admin Core$87,566
P01 · FY2025 · AI · contact PI
Broadly Effective HCV Vaccine$2,083,528
P01 · FY2024 · AI · contact PI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$1,168,511
R01 · FY2024 · AI
Novel Hepatitis B Vaccine and Immunotherapy$883,119
R56 · FY2024 · AI · contact PI
Understanding human antibody responses to chronic viral hepatitis C$626,827
R01 · FY2024 · AI · contact PI
Core 001 - Virology Core$354,183
P01 · FY2024 · AI · contact PI
Admin Core$86,137
P01 · FY2024 · AI · contact PI
Broadly Effective HCV Vaccine$2,083,528
P01 · FY2023 · AI · contact PI
Understanding human antibody responses to chronic viral hepatitis C$621,806
R01 · FY2023 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$542,012
R24 · FY2023 · AI
Core 001 - Virology Core$347,334
P01 · FY2023 · AI · contact PI
Admin Core$116,577
P01 · FY2023 · AI · contact PI
Broadly Effective HCV Vaccine$2,102,903
P01 · FY2022 · AI · contact PI
Understanding human antibody responses to chronic viral hepatitis C$621,806
R01 · FY2022 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$542,012
R24 · FY2022 · AI
Core 001 - Virology Core$354,184
P01 · FY2022 · AI · contact PI
Admin Core$86,137
P01 · FY2022 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$567,950
R24 · FY2021 · AI
Rheumatoid factor and cryoglobulinemia in chronic viral infection$241,875
R21 · FY2021 · AI · contact PI
Cooperative Center for the study of HCV antibody responses and vaccine antigens$888,265
U19 · FY2020 · AI · contact PI
Structure and function of Hepacivirus envelope glycoprotein$625,625
R01 · FY2020 · AI · contact PI
Antibody responses to HCV vaccine antigens in infection and vaccination$453,759
U19 · FY2020 · AI · contact PI
Rheumatoid factor and cryoglobulinemia in chronic viral infection$290,250
R21 · FY2020 · AI · contact PI
Administrative Core$177,621
U19 · FY2020 · AI · contact PI
Cooperative Center for the study of HCV antibody responses and vaccine antigens$907,122
U19 · FY2019 · AI · contact PI
Structure and function of Hepacivirus envelope glycoprotein$625,625
R01 · FY2019 · AI · contact PI
Antibody responses to HCV vaccine antigens in infection and vaccination$426,357
U19 · FY2019 · AI · contact PI
Administrative Core$167,090
U19 · FY2019 · AI · contact PI
Cooperative Center for the study of HCV antibody responses and vaccine antigens$918,736
U19 · FY2018 · AI · contact PI
Structure and function of Hepacivirus envelope glycoprotein$625,625
R01 · FY2018 · AI · contact PI
Antibody responses to HCV vaccine antigens in infection and vaccination$429,801
U19 · FY2018 · AI · contact PI
Administrative Core$172,727
U19 · FY2018 · AI · contact PI
Cooperative Center for the study of HCV antibody responses and vaccine antigens$918,736
U19 · FY2017 · AI · contact PI
Structure and function of Hepacivirus envelope glycoprotein$625,625
R01 · FY2017 · AI · contact PI
Understanding human neutralizing antibodies to hepatitis C virus$556,005
R01 · FY2017 · AI · contact PI
Dissecting virus neutralizing determinants to guide HCV vaccine development$457,124
R01 · FY2017 · AI · contact PI
Antibody responses to HCV vaccine antigens in infection and vaccination$424,742
U19 · FY2017 · AI · contact PI
Administrative Core$174,367
U19 · FY2017 · AI · contact PI
Cooperative Center for the study of HCV antibody responses and vaccine antigens$958,342
U19 · FY2016 · AI · contact PI
Structure and function of Hepacivirus envelope glycoprotein$625,625
R01 · FY2016 · AI · contact PI
Understanding human neutralizing antibodies to hepatitis C virus$556,005
R01 · FY2016 · AI · contact PI
Dissecting virus neutralizing determinants to guide HCV vaccine development$450,000
R01 · FY2016 · AI · contact PI
Antibody responses to HCV vaccine antigens in infection and vaccination$389,961
U19 · FY2016 · AI · contact PI
Administrative Core$278,641
U19 · FY2016 · AI · contact PI
Understanding human neutralizing antibodies to hepatitis C virus$548,397
R01 · FY2015 · AI · contact PI
Dissecting virus neutralizing determinants to guide HCV vaccine development$450,000
R01 · FY2015 · AI · contact PI
Understanding human neutralizing antibodies to hepatitis C virus$548,397
R01 · FY2014 · AI · contact PI
Dissecting virus neutralizing determinants to guide HCV vaccine development$175,312
R01 · FY2014 · AI · contact PI
Dissecting virus neutralizing determinants to guide HCV vaccine development$792,744
R56 · FY2013 · AI · contact PI
Understanding human neutralizing antibodies to hepatitis C virus$537,865
R01 · FY2013 · AI · contact PI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection$464,322
R01 · FY2011 · AI · contact PI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection$469,013
R01 · FY2010 · AI · contact PI
Hepatitis C virus E2 glycoprotein$237,375
R21 · FY2010 · AI · contact PI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection$473,750
R01 · FY2009 · AI · contact PI
Hepatitis C virus E2 glycoprotein$284,850
R21 · FY2009 · AI · contact PI
Discovery of potent human antibodies for prevention of (recurrent) HCV infection$473,750
R01 · FY2008 · AI · contact PI